Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Provectus Biopharmaceuticals Inc PVCT

Healthcare
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company’s lead molecule is named rose bengal sodium (RBS). The Company’s small molecule HX medical science platform... see more

Recent & Breaking News (OTCQB:PVCT)

PROVECTUS BIOPHARMACEUTICALS EXPANDS GLOBAL PATENT PORTFOLIO FOR CANCER COMBINATION THERAPY

GlobeNewswire April 18, 2018

Provectus Biopharmaceuticals Reestablishes Strategic Advisory Board

PR Newswire April 20, 2017

Provectus Biopharmaceuticals Closes Definitive Financing With PRH Group

PR Newswire April 4, 2017

Provectus Biopharmaceuticals Announces Terms Of Definitive Financing Commitment

PR Newswire March 23, 2017

Provectus Biopharmaceuticals Enters Into Definitive Financing Commitment Term Sheet

PR Newswire March 20, 2017

Provectus Biopharmaceuticals, Inc. Announces Extension Of Rights Offering Due To Receipt Of Unsolicited Investment Proposals To Invest In Provectus

PR Newswire March 6, 2017

Provectus Biopharmaceuticals Provides Information On Rights Offering Deadline

PR Newswire February 24, 2017

Provectus Biopharmaceuticals Appoints Bruce Horowitz And Dominic Rodrigues As Special Advisers To The Board Of Directors

PR Newswire February 23, 2017

Provectus Biopharmaceuticals, Inc. Announces Extension of Rights Offering

PR Newswire February 10, 2017

Provectus Biopharmaceuticals, Inc. Announces Commencement Of Rights Offering To Existing Stockholders And Holders Of Certain Warrants

PR Newswire January 31, 2017

Provectus Biopharmaceuticals Will Hold a Business Update Conference Call Thursday – January 5, 2017 at 9 a.m. (EST)

Business Wire January 3, 2017

Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO

Business Wire December 28, 2016

Drug Makers Stocks on Investors' Radar -- Provectus Biopharma, Novartis, TherapeuticsMD, and Tonix Pharma

PR Newswire December 27, 2016

Provectus Biopharmaceuticals Announces Two Poster Presentations on PV-10 for Liver Tumors

Business Wire December 22, 2016

Provectus Biopharmaceuticals Announces Agreement with POETIC (Pediatric Oncology Experimental Therapeutics Investigators Consortium) to Study Potential of PV-10 for Pediatric Cancer

Business Wire December 8, 2016

Provectus Biopharmaceuticals, Inc. Announces Notification of NYSE MKT Listing Deficiency

Business Wire November 30, 2016

Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 at Society for Immunotherapy of Cancer 2016 Annual Meeting

Business Wire November 14, 2016

Provectus Biopharmaceuticals Reports Third Quarter 2016 Financial Results

Business Wire November 10, 2016

Provectus Biopharmaceuticals Announces Data on PV-10 for Treatment of Pancreatic Cancer Scheduled for Poster Presentation at 31st SITC Annual Meeting

Business Wire November 2, 2016

Provectus Biopharmaceuticals to Present at Sidoti’s Fall 2016 Emerging Growth Conference, November 1, 2016

Business Wire October 27, 2016